Tag: ovarian cancer

Preliminary results from the ongoing Phase 1 study (NCT06555744) evaluating ZW191, an antibody-drug conjugate (see ADC Drugmap) targeting folate receptor-alpha (FR⍺), were presented at...

Results from the phase 2 dose optimization part of the REJOICE-Ovarian01 phase 2/3 trial (NCT06161025) showed that raludotatug deruxtecan (R-DXd, DS-6000a; see ADC Drugmap), a specifically engineered, potential first-in-class CDH6-directed antibody drug conjugate, discovered by Daiichi Sankyo and jointly developed by Daiichi Sankyo and Merck & Co (known as MSD outside of the United States and Canada), demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer.

The European Commission has granted marketing authorization for mirvetuximab soravtansine (Elahere®; AbbVie/ImmunoGen) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

Updated data from the ongoing Phase 1b study of luveltamab tazevibulin (luvelta; STRO-002; Sutro BioPharma) in combination with bevacizumab (Avastin®; Genentech/Roche) for patients with...

Updated results from the first-in-human phase 1 TORL123-001 (TRIO-049) trial (NCT05103683) investigating TOTL-1-23 (see: ADC Drugmap) in patients diagnosed with advanced or metastatic cancer, showed good tolerability and antitumor activity in heavily pretreated patients with ovarian and endometrial cancers that expressed claudin-6 (CLDN6).

Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.

Immunogen has submitted a Biologics License Application (BLA) under the accelerated approval pathway to the US Food and Drug Administration (FDA) for mirvetuximab soravtansine...

Folate receptor alpha (FolRα) is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies that can be used as a target for...

Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an ongoing expansion study evaluating XMT-1536...

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536...